A critical review of HER2-positive gastric cancer evaluation and treatment: From trastuzumab, and beyond

Cancer Letters

Volumn 351, Issue 1, 2014, Pages 30-40

  Gomez Martín, Carlos ^a,b   Lopez Rios, Fernando ^b   Aparicio, Jorge ^c   Barriuso, Jorge ^d   García Carbonero, Rocio ^e   Pazo, Roberto ^f   Rivera, Fernando ^g   Salgado, Mercedes ^h   Salud, Antonieta ⁱ   Vázquez Sequeiros, Enrique ^j   Lordick, Florian ^k  

^a HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^b UNIVERSIDAD SAN PABLO CEU   (Spain)

^c HOSPITAL UNIVERSITARIO LA FE   (Spain)

^d HOSPITAL UNIVERSITARIO LA PAZ IDIPAZ   (Spain)

^e HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

^f HOSPITAL UNIVERSITARIO MIGUEL SERVET   (Spain)

^g HOSPITAL UNIVERSITARIO MARQUÉS DE VALDECILLA   (Spain)

^h Hospital Neurotraumatológico   (Spain)

ⁱ HOSPITAL UNIVERSITARI ARNAU DE VILANOVA   (Spain)

^j HOSPITAL RAMÓN Y CAJAL   (Spain)

^k UNIVERSITY HOSPITAL LEIPZIG   (Germany)

more..

Author keywords

Gastric cancer; HER2; Review; Trastuzumab

Indexed keywords

CAPECITABINE; CISPLATIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FLUOROURACIL; LAPATINIB; PERTUZUMAB; TRASTUZUMAB;

ADVANCED CANCER; ANTINEOPLASTIC ACTIVITY; CANCER ADJUVANT THERAPY; CANCER DIAGNOSIS; CANCER PROGNOSIS; CANCER SURVIVAL; CLINICAL EFFECTIVENESS; DISEASE ACTIVITY; DOSE RESPONSE; DRUG APPROVAL; DRUG EFFICACY; DRUG FATALITY; DRUG MECHANISM; DRUG TARGETING; ENDOSCOPY; FLUORESCENCE IN SITU HYBRIDIZATION; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; MOLECULAR PATHOLOGY; MONOTHERAPY; NONHUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; SHORT SURVEY; SIGNAL TRANSDUCTION; STOMACH CANCER; STOMACH CARCINOGENESIS; SURVIVAL RATE; UNSPECIFIED SIDE EFFECT;

GASTRIC CANCER; HER2; REVIEW; TRASTUZUMAB;

ADENOCARCINOMA; ANIMALS; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; HUMANS; PROGNOSIS; RECEPTOR, ERBB-2; STOMACH NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 84903710545     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2014.05.019     Document Type: Review

References (120)

1. Jemal A., Siegel R., Ward E., Hao Y., Xu J., Thun M.J. Cancer statistics, 2009. CA Cancer J. Clin. 2009, 59(4):225-249.
2. Pasini F., Fraccon A.P., DE Manzoni G. The role of chemotherapy in metastatic gastric cancer. Anticancer Res. 2011, 31(10):3543-3554.
3. American Cancer Society, Survival Rates for Stomach Cancer by Stage, 2013, (accessed 05.09.13). http://www.cancer.org/cancer/stomachcancer/detailedguide/stomach-cancer-survival-rates.
4. Van Cutsem E., Dicato M., Geva R., Arber N., Bang Y., Benson A., Cervantes A., Diaz-Rubio E., Ducreux M., Glynne-Jones R., Grothey A., Haller D., Haustermans K., Kerr D., Nordlinger B., Marshall J., Minsky B.D., Kang Y.K., Labianca R., Lordick F., Ohtsu A., Pavlidis N., Roth A., Rougier P., Schmoll H.J., Sobrero A., Tabernero J., Van de Velde C., Zalcberg J. The diagnosis and management of gastric cancer: expert discussion and recommendations from the 12th ESMO/World congress on gastrointestinal cancer, Barcelona, 2010. Ann. Oncol. 2011, 22(suppl. 5):v1-9.
5. Lutz M.P., Zalcberg J.R., Ducreux M., Ajani J.A., Allum W., Aust D., Bang Y.J., Cascinu S., Hölscher A., Jankowski J., Jansen E.P., Kisslich R., Lordick F., Mariette C., Moehler M., Oyama T., Roth A., Rueschoff J., Ruhstaller T., Seruca R., Stahl M., Sterzing F., van Cutsem E., van der Gaast A., van Lanschot J., Ychou M., Otto F. First St. Gallen EORTC Gastrointestinal Cancer Conference 2012 Expert Panel, Highlights of the EORTC St. Gallen International Expert Consensus on the primary therapy of gastric, gastroesophageal and oesophageal cancer - differential treatment strategies for subtypes of early gastroesophageal cancer. Eur. J. Cancer 2012, 48(16):2941-2953.
6. Bang Y.J., Van Cutsem E., Feyereislova A., Chung H.C., Shen L., Sawaki A., Lordick F., Ohtsu A., Omuro Y., Satoh T., Aprile G., Kulikov E., Hill J., Lehle M., Rüschoff J., Kang Y.K. ToGA Trial Investigators, Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 2010, 376(9742):687-697.
7. Longo W.E., Zucker K.A., Zdon M.J., Modlin I.M. Detection of early gastric cancer in an aggressive endoscopy unit. Am. Surg. 1989, 55(2):100-104.
8. Ballantyne K.C., Morris D.L., Jones J.A., Gregson R.H., Hardcastle J.D. Accuracy of identification of early gastric cancer. Br. J. Surg. 1987, 74(7):618-619.
9. Gómez-Martín C., Concha A., Corominas J.M., García-Caballero T., García-García E., Iglesias M., López J.A., Ramón y Cajal S., Rojo F., Palacios J., Vera-Sempere F., Aranda E., Colomer R., García-Alfonso P., Garrido P., Rivera F., López-Río F. Spanish Society of Medical Oncology, Spanish Society of Pathology, Consensus of the Spanish Society of Medical Oncology (SEOM) and Spanish Society of Pathology (SEAP) for HER2 testing in gastric carcinoma. Clin. Transl. Oncol. 2011, 13(9):636-651.
10. Wang H.H., Jonasson J.G., Ducatman B.S. Brushing cytology of the upper gastrointestinal tract. obsolete or not?. Acta Cytol. 1991, 35(2):195-198.
11. Graham D.Y., Schwartz J.T., Cain G.D., Gyorkey F. Prospective evaluation of biopsy number in the diagnosis of esophageal and gastric carcinoma. Gastroenterology 1982, 82(2):228-231.
12. Choi Y., Choi H.S., Jeon W.K., Kim B.I., Park D.I., Cho Y.K., Kim H.J., Park J.H., Sohn C.I. Optimal number of endoscopic biopsies in diagnosis of advanced gastric and colorectal cancer. J. Korean Med. Sci. 2012, 27(1):36-39.
13. Warneke V.S., Behrens H.M., Böger C., Becker T., Lordick F., Ebert M.P., Röcken C. HER2/neu testing in gastric cancer: evaluating the risk of sampling errors. Ann. Oncol. 2013, 24(3):725-733.
14. Nagahama T., Yao K., Maki S., Yasaka M., Takaki Y., Matsui T., Tanabe H., Iwashita A., Ota A. Usefulness of magnifying endoscopy with narrow-band imaging for determining the horizontal extent of early gastric cancer when there is an unclear margin by chromoendoscopy (with video). Gastrointest. Endosc. 2011, 74(6):1259-1267.
15. Karita M., Tada M. Endoscopic and histologic diagnosis of submucosal tumors of the gastrointestinal tract using combined strip biopsy and bite biopsy. Gastrointest. Endosc. 1994, 40(6):749-753.
16. Mastoraki A., Papanikolaou I.S., Sakorafas G., Safioleas M. Facing the challenge of managing linitis plastica-review of the literature. Hepatogastroenterology 2009, 56(96):1773-1778.
17. WHO classification of tumours of the digestive system, in: F.T. Bosman, F. Carneiro, R.H. Hruban, N.D. Theise (Eds.), WHO Classification of Tumours. Fourth Edition. Lyon, France, International Agency for Research in Cancer, 2010, pp. 43.
18. Herceptin Summary of Product Characteristics. Roche, 2010, (accessed 14.12.13). http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000278/WC500074922.pdf.
19. Gómez-Martin C., Garralda E., Echarri M.J., Ballesteros A., Arcediano A., Rodríguez-Peralto J.L., Hidalgo M., López-Ríos F. HER2/neu testing for anti-HER2-based therapies in patients with unresectable and/or metastatic gastric cancer. J. Clin. Pathol. 2012, 65(8):751-757.
20. Giuffre G., Ieni A., Barresi V., Caruso R.A., Tuccari G. HER2 status in unusual histological variants of gastric adenocarcinomas. J. Clin. Pathol. 2012, 65(3):237-241.
21. Boers J.E., Meeuwissen H., Methorst N. HER2 status in gastro-oesophageal adenocarcinomas assessed by two rabbit monoclonal antibodies (SP3 and 4B5) and two in situ hybridization methods (FISH and SISH). Histopathology 2011, 58(3):383-394.
22. Rüschoff J., Hanna W., Bilous M., Hofmann M., Osamura R.Y., Penault-Llorca F., van de Vijver M., Viale G. HER2 testing in gastric cancer: a practical approach. Mod. Pathol. 2012, 25(5):637-650.
23. Yan B., Yau E.X., Choo S.N., Ong C.W., Yong K.J., Pang B., Salto-Tellez M. Dual-colour HER2/chromosome 17 chromogenic in situ hybridisation assay enables accurate assessment of HER2 genomic status in gastric cancer and has potential utility in HER2 testing of biopsy samples. J. Clin. Pathol. 2011, 64(10):880-883.
24. Stenzinger A., von Winterfeld M., Aulmann S., Warth A., Weichert W., Denkert C., Rüschoff J., Dietel M., Klauschen F. Quantitative analysis of diagnostic guidelines for HER2-status assessment. J. Mol. Diagn. 2012, 14(3):199-205.
25. García-García E., Gómez-Martín C., Angulo B., Conde E., Suárez-Gauthier A., Adrados M., Perna C., Rodríguez-Peralto J.L., Hidalgo M., López-Ríos F. Hybridization for human epidermal growth factor receptor 2 testing in gastric carcinoma: a comparison of fluorescence in-situ hybridization with a novel fully automated dual-colour silver in situ hybridization method. Histopathology 2011, 59(1):8-17.
26. Radu O.M., Foxwell T., Cieply K., Navina S., Dacic S., Nason K.S., Davison J.M. HER2 amplification in gastroesophageal adenocarcinoma: correlation of two antibodies using gastric cancer scoring criteria H score, and digital image analysis with fluorescence in situ hybridization. Am. J. Clin. Pathol. 2012, 137(4):583-594.
27. Cho E.Y., Srivastava A., Park K., Kim J., Lee M.H., Do I., Lee J., Kim K.M., Sohn T.S., Kang W.K., Kim S. Comparison of four immunohistochemical tests and FISH for measuring HER2 expression in gastric carcinomas. Pathology 2012, 44(3):216-220.
28. Bartlett J.M., Starczynski J., Atkey N., Kay E., O'Grady A., Gandy M., Ibrahim M., Jasani B., Ellis I.O., Pinder S.E., Walker R.A. HER2 testing in the UK: recommendations for breast and gastric in-situ hybridisation methods. J. Clin. Pathol. 2011, 64(8):649-653.
29. Choritz H., Busche G., Kreipe H. Study Group HER2 Monitor, quality assessment of HER2 testing by monitoring of positivity rates. Virchows Arch. 2011, 459(3):283-289.
30. Yoon H.H., Shi Q., Sukov W.R., Lewis M.A., Sattler C.A., Wiktor A.E., Wu T.T., Diasio R.B., Jenkins R.B., Sinicrope F.A. Adverse prognostic impact of intratumor heterogeneous HER2 gene amplification in patients with esophageal adenocarcinoma. J. Clin. Oncol. 2012, 30(32):3932-3938.
31. Yang J., Luo H., Li Y., Li J., Cai Z., Su X., Dai D., Du W., Chen T., Chen M. Intratumoral heterogeneity determines discordant results of diagnostic tests for human epidermal growth factor receptor (HER) 2 in gastric cancer specimens. Cell Biochem. Biophys. 2012, 62(1):221-228.
32. Kim M.A., Lee H.J., Yang H.K., Bang Y.J., Kim W.H. Heterogeneous amplification of ERBB2 in primary lesions is responsible for the discordant ERBB2 status of primary and metastatic lesions in gastric carcinoma. Histopathology 2011, 59(5):822-831.
33. Negri F.V., Bozzetti C., Ardizzoni A., Lagrasta C., Crafa P., Silini E.M. HER-2 discordance between primary gastric carcinoma and paired lymph node metastasis. Hum. Pathol. 2011, 42(6):909-910. (author reply 910-911).
34. Lee S., de Boer W.B., Fermoyle S., Platten M., Kumarasinghe M.P. Human epidermal growth factor receptor 2 testing in gastric carcinoma: issues related to heterogeneity in biopsies and resections. Histopathology 2011, 59(5):832-840.
35. Watson S., Validire P., Cervera P., Zorkani N., Scriva A., Lemay F., Tournigand C., Perniceni T., Garcia M.L., Bennamoun M., Paye F., Louvet C. Combined HER2 analysis of biopsies and surgical specimens to optimize detection of trastuzumab-eligible patients in eso-gastric adenocarcinoma: a GERCOR study. Ann. Oncol. 2013, 24(12):3035-3039.
36. Bloom K.J., Cote R.J. Counterpoint: both immunohistochemistry and fluorescence in situ hybridization play important roles for HER2 evaluation. Clin. Chem. 2011, 57(7):983-985.
37. Salto-Tellez M., Yau E.X., Yan B., Fox S.B. Where and by whom should gastric cancer HER2/neu status be assessed? Lessons from breast cancer. Arch. Pathol. Lab. Med. 2011, 135(6):693-695.
38. Fox S.B., Kumarasinghe M.P., Armes J.E., Bilous M., Cummings M.C., Farshid G., Fitzpatrick N., Francis G.D., McCloud P.I., Raymond W., Morey A. Gastric HER2 testing study (GaTHER): an evaluation of gastric/gastroesophageal junction cancer testing accuracy in Australia. Am. J. Surg. Pathol. 2012, 36(4):577-582.
39. Tafe L.J., Janjigian Y.Y., Zaidinski M., Hedvat C.V., Hameed M.R., Tang L.H., Hicks J.B., Shah M.A., Barbashina V. Human epidermal growth factor receptor 2 testing in gastroesophageal cancer: correlation between immunohistochemistry and fluorescence in situ hybridization. Arch. Pathol. Lab. Med. 2011, 135(11):1460-1465.
40. Gomez-Martin C., Plaza J.C., Pazo-Cid R., Salud A., Pons F., Fonseca P., Leon A., Alsina M., Visa L., Rivera F., Galan M.C., Del Valle E., Vilardell F., Iglesias M., Fernandez S., Landolfi S., Cuatrecasas M., Mayorga M., Jose Paulés M., Sanz-Moncasi P., Montagut C., Garralda E., Rojo F., Hidalgo M., Lopez-Rios F. Level of HER2 Gene amplification predicts response and overall survival in HER2-positive advanced gastric cancer treated with trastuzumab. J. Clin. Oncol. 2013, 31(35):4445-4452.
41. Kunz P.L., Mojtahed A., Fisher G.A., Ford J.M., Chang D.T., Balise R.R., Bangs C.D., Cherry A.M., Pai R.K. HER2 expression in gastric and gastroesophageal junction adenocarcinoma in a US population: clinicopathologic analysis with proposed approach to HER2 assessment. Appl. Immunohistochem. Mol. Morphol. 2012, 20(1):13-24.
42. Pusztai L., Viale G., Kelly C.M., Hudis C.A. Estrogen and HER-2 receptor discordance between primary breast cancer and metastasis. Oncologist 2010, 15(11):1164-1168.
43. Wagner A.D., Unverzagt S., Grothe W., Kleber G., Grothey A., Haerting J., Fleig W.E. Chemotherapy for advanced gastric cancer. Cochrane Database Syst. Rev. 2010, 3. CD004064.
44. Wagner A.D., Grothe W., Haerting J., Kleber G., Grothey A., Fleig W.E. Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data. J. Clin. Oncol. 2006, 24(18):2903-2909.
45. Van Cutsem E., Moiseyenko V.M., Tjulandin S., Majlis A., Constenla M., Boni C., Rodrigues A., Fodor M., Chao Y., Voznyi E., Risse M.L., Ajani J.A. V325 Study Group, Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 study group. J. Clin. Oncol. 2006, 24(31):4991-4997.
46. Lordick F., Lorenzen S., Yamada Y., Ilson D. Optimal chemotherapy for advanced gastric cancer: is there a global consensus?. Gastric Cancer 2013, September 19 (Epub ahead of print).
47. Cunningham D., Starling N., Rao S., Iveson T., Nicolson M., Coxon F., Middleton G., Daniel F., Oates J., Norman A.R. Upper Gastrointestinal Clinical Studies Group of the National Cancer Research Institute of the United Kingdom Capecitabine and oxaliplatin for advanced esophagogastric cancer. New Engl. J. Med. 2008, 358(1):36-46.
48. Dank M., Zaluski J., Barone C., Valvere V., Yalcin S., Peschel C., Wenczl M., Goker E., Cisar L., Wang K., Bugat R. Randomized phase III study comparing irinotecan combined with 5-fluorouracil and folinic acid to cisplatin combined with 5-fluorouracil in chemotherapy naive patients with advanced adenocarcinoma of the stomach or esophagogastric junction. Ann. Oncol. 2008, 19(8):1450-1457.
49. Ajani J.A., Rodriguez W., Bodoky G., Moiseyenko V., Lichinitser M., Gorbunova V., Vynnychenko I., Garin A., Lang I., Falcon S. Multicenter phase III comparison of cisplatin/S-1 with cisplatin/infusional fluorouracil in advanced gastric or gastroesophageal adenocarcinoma study: the FLAGS trial. J. Clin. Oncol. 2010, 28(9):1547-1553.
50. Fuchs C.S., Tomasek J., Yong C.J., Dumitru F., Passalacqua R., Goswami C., Safran H., Dos Santos L.V., Aprile G., Ferry D.R., Melichar B., Tehfe M., Topuzov E., Zalcberg J.R., Chau I., Campbell W., Sivanandan C., Pikiel J., Koshiji M., Hsu Y., Liepa A.M., Gao L., Schwartz J.D., Tabernero J. For the REGARD Trial Investigators, Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet 2014, 383(9911):31-39.
51. Kang J.H., Lee S.I., Lim do H., Park K.W., Oh S.Y., Kwon H.C., Hwang I.G., Lee S.C., Nam E., Shin D.B., Lee J., Park J.O., Park Y.S., Lim H.Y., Kang W.K., Park S.H. Salvage chemotherapy for pretreated gastric cancer: a randomized phase III trial comparing chemotherapy plus best supportive care with best supportive care alone. J. Clin. Oncol. 2012, 30(13):1513-1518.
52. Power D.G., Kelsen D.P., Shah M.A. Advanced gastric cancer-slow but steady progress. Cancer Treat. Rev. 2010, 36(5):384-392.
53. Rebischung C., Barnoud R., Stefani L., Faucheron J.L., Mousseau M. The effectiveness of trastuzumab (herceptin) combined with chemotherapy for gastric carcinoma with overexpression of the c-erbB-2 protein. Gastric Cancer 2005, 8(4):249-252.
54. Inui T., Asakawa A., Morita Y., Mizuno S., Natori T., Kawaguchi A., Murakami M., Hishikawa Y., Inui A. HER-2 overexpression and targeted treatment by trastuzumab in a very old patient with gastric cancer. J. Intern. Med. 2006, 260(5):484-487.
55. Nicholas G., Cripps C., Au H.J., Jonker D., Salim M., Bjarnason G., Chiritescu G. Early results of a trial of trastuzumab, cisplatin and docetaxel (TCD) for the treatment of metastatic gastric cancer overexpressing HER2. Ann. Oncol. 2006, 17(suppl. 9). ix316 (abstract 1105P).
56. Rech J., Arnold D., Folprecht G., Hejna M., Hofmann M., Gramatzki M. A pilot study of trastuzumab monotherapy in patients who progressed while on chemotherapy for metastatic or locally advanced HER positive gastric cancer. Ann. Oncol. 2006, 17(suppl. 9). ix314 (abstract 1096P).
57. Grávalos C., Gómez-Martín C., Rivera F., Alés I., Queralt B., Márquez A., Jiménez U., Alonso V., García-Carbonero R., Sastre J., Colomer R., Cortés-Funes H., Jimeno A. Phase II study of trastuzumab and cisplatin as first-line therapy in patients with HER2-positive advanced gastric or gastroesophageal junction cancer. Clin. Transl. Oncol. 2011, 13(3):179-184.
58. Tanner M., Hollmén M., Junttila T.T., Kapanen A.I., Tommola S., Soini Y., Helin H., Salo J., Joensuu H., Sihvo E., Elenius K., Isola J. Amplification of HER-2 in gastric carcinoma: Association with topoisomerase IIalpha gene amplification, intestinal type, poor prognosis and sensitivity to trastuzumab. Ann. Oncol. 2005, 16(2):273-278.
59. Park D.I., Yun J.W., Park J.H., Oh S.J., Kim H.J., Cho Y.K., Sohn C.I., Jeon W.K., Kim B.I., Yoo C.H., Son B.H., Cho E.Y., Chae S.W., Kim E.J., Sohn J.H., Ryu S.H., Sepulveda A.R. HER-2/neu amplification is an independent prognostic factor in gastric cancer. Dig. Dis. Sci. 2006, 51(8):1371-1379.
60. Janjigian Y.Y., Werner D., Pauligk C., Steinmetz K., Kelsen D.P., Jäger E., Altmannsberger H.M., Robinson E., Tafe L.J., Tang L.H., Shah M.A., Al-Batran S.E. Prognosis of metastatic gastric and gastroesophageal junction cancer by HER2 status: a European and USA International collaborative analysis. Ann. Oncol. 2012, 23(10):2656-2662.
61. Yamashita K., Sakuramoto S., Katada N., Futawatari N., Moriya H., Hirai K., Kikuchi S., Watanabe M. Diffuse type advanced gastric cancer showing dismal prognosis is characterized by deeper invasion and emerging peritoneal cancer cell: the latest comparative study to intestinal advanced gastric cancer. Hepatogastroenterology 2009, 56(89):276-281.
62. Miyahara R., Niwa Y., Matsuura T., Maeda O., Ando T., Ohmiya N., Itoh A., Hirooka Y., Goto H. Prevalence and prognosis of gastric cancer detected by screening in a large japanese population: data from a single institute over 30years. J. Gastroenterol. Hepatol. 2007, 22(9):1435-1442.
63. NCCN guidelines version 2.2012 gastric cancer, Principles of Systemic Therapy (GAST-E), 2012, (accessed 16.12.13). http://www.nccn.org/professionals/physician_gls/pdf/gastric.pdf.
64. Holden J., Garrett Z., Stevens A. NICE guidance on trastuzumab for the treatment of HER2-positive metastatic gastric cancer. Lancet Oncol. 2011, 12(1):16-17.
65. Rivera F., Gravalos C., Garcia-Carbonero R. SEOM clinical guidelines for the diagnosis and treatment of gastric adenocarcinoma. Clin. Transl. Oncol. 2012, 14(7):528-535.
66. Okines A., Verheij M., Allum W., Cunningham D., Cervantes A. ESMO Guidelines Working Group Gastric cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 2010, 21(suppl. 5):v50-v54.
67. Dai G.H., Shi Y., Chen L., Lv Y.L., Zhong M. Trastuzumab combined with docetaxel-based regimens in previously treated metastatic gastric cancer patients with HER2 over-expression. Hepatogastroenterology 2012, 59(120):2439-2444.
68. Siewert J.R., Böttcher K., Stein H.J., Roder J.D. Relevant prognostic factors in gastric cancer: ten-year results of the German Gastric Cancer Study. Ann. Surg. 1998, 228(4):449-461.
69. Cunningham D., Allum W.H., Stenning S.P., Thompson J.N., Van de Velde C.J., Nicolson M., Scarffe J.H., Lofts F.J., Falk S.J., Iveson T.J., Smith D.B., Langley R.E., Verma M., Weeden S., Weeden Y.J MAGIC Trial Participants, Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. New Engl. J. Med. 2006, 355(1):11-20.
70. Rivera F., Jiménez P., Garcia Alfonso P., Lopez C., Gallego J., Limon M.L., Alsina M., Lopez-Gomez L., Galán M., Falco E., Manzano J.L., González E., Serrano R., Fernandez Parra E., Jorge M. NeoHx study: perioperative treatment with trastuzumab in combination with capecitabine and oxaliplatin (XELOX-T) in patients with HER2 resectable stomach or esophagogastric junction (EGJ) adenocarcinoma-R0 resection, pCR, and toxicity analysis. J. Clin. Oncol. 2013, 31. suppl; abstr 4098.
71. Kim H.P., Han S.W., Kim S.H., Im S.A., Oh D.Y., Bang Y.J., Kim T.Y. Combined lapatinib and cetuximab enhance cytotoxicity against gefitinib-resistant lung cancer cells. Mol. Cancer Ther. 2008, 7:607-615.
72. J. Hecht, G. Urba, M. Koehler, C. Ellis, Lapatinib Monotherapy in Recurrent Upper Gastrointestinal Malignancy: Phase II Efficacy and Biomarker Analyses, Proc. GI ASCO, vol. 43, 2008 (abstract 43).
73. Iqbal S., Goldman B., Fenoglio-Preiser C.M., Lenz H.J., Zhang W., Danenberg K.D., Shibata S.I., Blanke C.D. Southwest oncology group study S0413: a phase II trial of lapatinib (GW572016) as first-line therapy in patients with advanced or metastatic gastric cancer. Ann. Oncol. 2011, 22(12):2610-2615.
74. M. Pishvaian, D. Sakaeva, R.K. Hsieh, S.Y. Rha, G. Caderillo-Ruiz, W.H. Miller Jr., A.M. Kemner, Y.M. Nagarwala, W. Zhang, H. Lenz, A global, Multicenter Phase II Trial of Lapatinib Plus Capecitabine in Gastric Cancer, ASCO Meeting Abstracts, vol. 29(4_suppl), 2011, pp. 88.
75. Y.J. Bang, A randomized, open-label, phase III study of lapatinib in combination with weekly paclitaxel versus weekly paclitaxel alone in the second-line treatment of HER2 amplified advanced gastric cancer (AGC) in Asian population: Tytan study. ASCO Gastrointestinal Cancers Symposium Abstracts, vol. 30, 2013 (suppl 34; abstr 11).
76. Hecht J.R., Bang Y.J., Qin S., Chung H.C., Xu J.M., Park J.O., Jeziorski K., Shparyk Y., Hoff P.M., Sobrero A.F., Salman P., Li J., Protsenko S., Buyse M.E., Afenjar K., Kaneko T., Kemner A., Santillana S., Press M.F., Slamon D.J. Lapatinib in combination with capecitabine plus oxaliplatin (CapeOx) in HER2-positive advanced or metastatic gastric, esophageal, or gastroesophageal adenocarcinoma (AC): the TRIO-013/LOGiC Trial. J. Clin. Oncol. 2013, 31. (suppl; abstr LBA4001).
77. Barok M., Tanner M., Koninki K., Isola J. Trastuzumab-DM1 is highly effective in preclinical models of HER2-positive gastric cancer. Cancer Lett. 2011, 306(2):171-179.
78. Nam H.J., Ching K.A., Kan J., Kim H.P., Han S.W., Im S.A., Kim T.Y., Christensen J.G., Oh D.Y., Bang Y.J. Evaluation of the antitumor effects and mechanisms of PF00299804, a pan-HER inhibitor, alone or in combination with chemotherapy or targeted agents in gastric cancer. Mol. Cancer Ther. 2012, 11(2):439-451.
79. Nam H.J., Kim H.P., Yoon Y.K., Hur H.S., Song S.H., Kim M.S., Lee G.S., Han S.W., Im S.A., Kim T.Y., Oh D.Y., Bang Y.J. Antitumor activity of HM781-36B, an irreversible pan-HER inhibitor, alone or in combination with cytotoxic chemotherapeutic agents in gastric cancer. Cancer Lett. 2011, 302(2):155-165.
80. D. Oh, K. Lee, J.Y. Cho, W.K. Kang, S.Y. Rha, Y. Bang, A phase II open-label trial of dacomitinib monotherapy in patients with HER2-positive advanced gastric cancer after failure of at least one prior chemotherapy regimen, ASCO Meeting Abstracts, vol. 30(4_suppl), 2012, pp. 54.
81. Y.Y. Janjigian, D. Ilson, D.P. Kelsen, M. Schattner, A. Heguy, E. Vakiani, A phase II study of afatinib (BIBW 2992) in patients with advanced HER2-positive trastuzumab-refractory esophagogastric cancer, ASCO Meeting Abstracts, vol. 30(15_suppl), 2012, pp. TPS4144.
82. Wainberg Z.A., Anghel A., Desai A.J., Ayala R., Luo T., Safran B., Fejzo M.S., Hecht J.R., Slamon D.J., Finn R.S. Lapatinib, a dual EGFR and HER2 kinase inhibitor, selectively inhibits HER2-amplified human gastric cancer cells and is synergistic with trastuzumab in vitro and in vivo. Clin. Cancer Res. 2010, 16(5):1509-1519.
83. Mimura K., Kono K., Maruyama T., Watanabe M., Izawa S., Shiba S., Mizukami Y., Kawaguchi Y., Inoue M., Kono T., Choudhury A., Kiessling R., Fujii H. Lapatinib inhibits receptor phosphorylation and cell growth and enhances antibody-dependent cellular cytotoxicity of EGFR- and HER2-overexpressing esophageal cancer cell lines. Int. J. Cancer 2011, 129(10):2408-2416.
84. Scaltriti M., Verma C., Guzman M., Jimenez J., Parra J.L., Pedersen K., Smith D.J., Landolfi S., Ramon y Cajal S., Arribas J., Baselga J. Lapatinib, a HER2 tyrosine kinase inhibitor, induces stabilization and accumulation of HER2 and potentiates trastuzumab-dependent cell cytotoxicity. Oncogene 2009, 28(6):803-814.
85. Blackwell K.L., Burstein H.J., Storniolo A.M., Rugo H., Sledge G., Koehler M., Ellis C., Casey M., Vukelja S., Bischoff J., Baselga J., O'Shaughnessy J. Randomized study of lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer. J. Clin. Oncol. 2010, 28(7):1124-1130.
86. Baselga J., Cortés J., Kim S.B., Im S.A., Hegg R., Im Y.H., Roman L., Pedrini J.L., Pienkowski T., Knott A., Clark E., Benyunes M.C., Ross G., Swain S.M. CLEOPATRA Study Group Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N. Engl. J. Med. 2012, 366(2):109-119.
87. Yamashita-Kashima Y., Iijima S., Yorozu K., Furugaki K., Kurasawa M., Ohta M., Fujimoto-Ouchi K. Pertuzumab in combination with trastuzumab shows significantly enhanced antitumor activity in HER2-positive human gastric cancer xenograft models. Clin. Cancer Res. 2011, 17(15):5060-5070.
88. Guertin D.A., Sabatini D.M. Defining the role of mTOR in cancer. Cancer Cell 2007, 12(1):9-22.
89. Miller T.W., Forbes J.T., Shah C., Wyatt S.K., Manning H.C., Olivares M.G., Sanchez V., Dugger T.C., de Matos Granja N., Narasanna A., Cook R.S., Kennedy J.P., Lindsley C.W., Arteaga C.L. Inhibition of mammalian target of rapamycin is required for optimal antitumor effect of HER2 inhibitors against HER2-overexpressing cancer cells. Clin. Cancer Res. 2009, 15(23):7266-7276.
90. Morrow P.K., Wulf G.M., Ensor J., Booser D.J., Moore J.A., Flores P.R., Xiong Y., Zhang S., Krop I.E., Winer E.P., Kindelberger D.W., Coviello J., Sahin A.A., Nuñez R., Hortobagyi G.N., Yu D., Esteva F.J. Phase I/II study of trastuzumab in combination with everolimus (RAD001) in patients with HER2-overexpressing metastatic breast cancer who progressed on trastuzumab-based therapy. J. Clin. Oncol. 2011, 29(23):3126-3132.
91. Doi T., Muro K., Boku N., Yamada Y., Nishina T., Takiuchi H., Komatsu Y., Hamamoto Y., Ohno N., Fujita Y., Robson M., Ohtsu A. Multicenter phase II study of everolimus in patients with previously treated metastatic gastric cancer. J. Clin. Oncol. 2010, 28:1904-1910.
92. Ohtsu A., Ajani J.A., Bai Y.X., Bang Y.J., Chung H.C., Pan H.M., Sahmoud T., Shen L., Yeh K.H., Chin K., Muro K., Kim Y.H., Ferry D., Tebbutt N.C., Al-Batran S.E., Smith H., Costantini C., Rizvi S., Lebwohl D., Van Cutsem E. Everolimus for previously treated advanced gastric cancer: results of the randomized, double-blind, phase III GRANITE-1 study. J. Clin. Oncol. 2013, 31(31):3935-3943.
93. Lennerz J.K., Kwak E.L., Ackerman A., Michael M., Fox S.B., Bergethon K., Lauwers G.Y., Christensen J.G., Wilner K.D., Haber D.A., Salgia R., Bang Y.J., Clark J.W., Solomon B.J., Iafrate A.J. MET amplification identifies a small and aggressive subgroup of esophagogastric adenocarcinoma with evidence of responsiveness to crizotinib. J. Clin. Oncol. 2011, 29(36):4803-4810.
94. Kubicka S., Claas C., Staab S., Kühnel F., Zender L., Trautwein C., Wagner S., Rudolph K.L., Manns M. P53 mutation pattern and expression of c-erbB2 and c-met in gastric cancer: relation to histological subtypes, helicobacter pylori infection, and prognosis. Dig. Dis. Sci. 2002, 47(1):114-121.
95. Chen C.T., Kim H., Liska D., Gao S., Christensen J.G., Weiser M.R. MET activation mediates resistance to lapatinib inhibition of HER2-amplified gastric cancer cells. Mol. Cancer Ther. 2012, 11(3):660-669.
96. Kataoka Y., Mukohara T., Tomioka H., Funakoshi Y., Kiyota N., Fujiwara Y., Yashiro M., Hirakawa K., Hirai M., Minami H. Foretinib (GSK1363089), a multi-kinase inhibitor of MET and VEGFRs, inhibits growth of gastric cancer cell lines by blocking inter-receptor tyrosine kinase networks. Invest. New Drugs 2012, 30(4):1352-1360.
97. Bardelli A., Corso S., Bertotti A., Hobor S., Valtorta E., Siravegna G, Sartore-Bianchi A., Scala E., Cassingena A., Zecchin D., Apicella M., Migliardi G., Galimi F., Lauricella C., Zanon C., Perera T., Veronese S., Corti G., Amatu A., Gambacorta M., Diaz L.A., Sausen M., Velculescu V.E., Comoglio P., Trusolino L., Di Nicolantonio F., Giordano S., Siena S. Amplification of the MET receptor drives resistance to Anti-EGFR therapies in colorectal cancer. Cancer Discov. 2013, 3(6):658-673.
98. Iveson T. Evaluation of MET pathway biomarkers in a phase II study of rilotumumab (R, AMG 102) or placebo (P) in combination with epirubicin, cisplatin, and capecitabine (ECX) in patients (pts) with locally advanced or metastatic gastric (G) or esophagogastric junction (EGJ) cancer. J. Clin. Oncol. 2012, 30. (suppl; abstr 4005).
99. Bertotti A., Bracco C., Girolami F., Torti D., Gastaldi S., Galimi F., Medico E., Elvin P., Comoglio P.M., Trusolino L. Inhibition of src impairs the growth of met-addicted gastric tumors. Clin. Cancer Res. 2010, 16(15):3933-3943.
100. Ono N., Yamazaki T., Nakanishi Y., Fujii T., Sakata K., Tachibana Y., Suda A., Hada K., Miura T., Sato S., Saitoh R., Nakano K., Tsukuda T., Mio T., Ishii N., Kondoh O., Aoki Y. Preclinical antitumor activity of the novel heat shock protein 90 inhibitor CH5164840 against human epidermal growth factor receptor 2 (HER2)-overexpressing cancers. Cancer Sci. 2012, 103(2):342-349.
101. Owens M.A., Horten B.C., Da Silva M.M. HER2 amplification ratios by fluorescence in situ hybridization and correlation with immunohistochemistry in a cohort of 6556 breast cancer tissues. Clin. Breast Cancer 2004, 5(1):63-69.
102. Hofmann M., Stoss O., Shi D., Büttner R., van de Vijver M., Kim W., Ochiai A., Rüschoff J., Henkel T. Assessment of a HER2 scoring system for gastric cancer: results from a validation study. Histopathology 2008, 52(7):797-805.
103. Bilous M., Osamura R.Y., Rüschoff J., van de Vijver M., Hanna W., Penault-Llorca F., Roche P. HER-2 amplification is highly homogenous in gastric cancer. Hum. Pathol. 2010, 41(2):304-305. (author reply 305-306).
104. Gravalos C., Jimeno A. HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target. Ann. Oncol. 2008, 19(9):1523-1529.
105. Lordick F. Trastuzumab: a new treatment option for HER2-positive metastatic gastric and gastroesophageal junction cancer. Future Oncol. 2011, 7(2):187-199.
106. Vu T., Claret F.X. Trastuzumab: updated mechanisms of action and resistance in breast cancer. Front Oncol. 2012, 2:62.
107. Pedrazzani C., Corso G., Marrelli D., Roviello F. E-cadherin and hereditary diffuse gastric cancer. Surgery 2007, 142(5):645-657.
108. Seidman A., Hudis C., Pierri M.K., Shak S., Paton V., Ashby M., Murphy M., Stewart S.J., Keefe D. Cardiac dysfunction in the trastuzumab clinical trials experience. J. Clin. Oncol. 2002, 20(5):1215-1221.
109. Vogel C.L., Cobleigh M.A., Tripathy D., Gutheil J.C., Harris L.N., Fehrenbacher L., Slamon D.J., Murphy M., Novotny W.F., Burchmore M., Shak S., Stewart S.J., Press M. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J. Clin. Oncol. 2002, 20(3):719-726.
110. Baselga J., Bradbury I., Eidtmann H., Di Cosimo S., de Azambuja E., Aura C., Gómez H., Dinh P., Fauria K., Van Dooren V., Aktan G., Goldhirsch A., Chang T.W., Horváth Z., Coccia-Portugal M., Domont J., Tseng L.M., Kunz G., Sohn J.H., Semiglazov V., Lerzo G., Palacova M., Probachai V., Pusztai L., Untch M., Gelber R.D. M Piccart-Gebhart; NeoALTTO Study Team, Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial. Lancet 2012, 379(9816):633-640.
111. Burris H.A., Rugo H.S., Vukelja S.J., Vogel C.L., Borson R.A., Limentani S., Tan-Chiu E., Krop I.E., Michaelson R.A., Girish S., Amler L., Zheng M., Chu Y.W., Klencke B., O'Shaughnessy J.A. Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer after prior HER2-directed therapy. J. Clin. Oncol. 2011, 29(4):398-405.
112. Starczynski J., Atkey N., Connelly Y., O'Grady T., Campbell F.M., di Palma S., Wencyk P., Jasani B., Gandy M., Bartlett J.M. UKNEQAS, HER2 gene amplification in breast cancer: a rogues' gallery of challenging diagnostic cases: UKNEQAS interpretation guidelines and research recommendations. Am. J. Clin. Pathol. 2012, 137(4):595-605.
113. Rasmussen B.B., Andersson M., Christensen I.J., Moller S. Evaluation of and quality assurance in HER2 analysis in breast carcinomas from patients registered in danish breast cancer group (DBCG) in the period of 2002-2006. A nationwide study including correlation between HER-2 status and other prognostic variables. Acta Oncol. 2008, 47(4):784-788.
114. Wolff A.C., Hammond M.E.H., Hicks D.G., Dowsett M., McShane L.M., Allison K.H., Allred D.C., Bartlett J.M.S., Bilous M., Fitzgibbons P., Hanna W., Jenkins R.B., Mangu P.B., Paik S., Perez E.A., Press M.F., Spears P.A., Vance G.H., Viale G., Hayes D.F. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Update. J. Clin. Oncol. 2013, 31:3997-4013.
115. Rüschoff J., Dietel M., Baretton G., Arbogast S., Walch A., Monges G., Chenard M.P., Penault-Llorca F., Nagelmeier I., Schlake W., Höfler H., Kreipe H.H. HER2 diagnostics in gastric cancer-guideline validation and development of standardized immunohistochemical testing. Virchows Arch. 2010, 457(3):299-307.
116. Penault-Llorca F., Bilous M., Dowsett M., Hanna W., Osamura R.Y., Rüschoff J., van de Vijver M. Emerging technologies for assessing HER2 amplification. Am. J. Clin. Pathol. 2009, 132(4):539-548.
117. Perrone G., Amato M., Callea M., Rabitti C., Righi D., Crucitti P., Coppola R., Onetti Muda A. HER2 amplification status in gastric and gastro-oesophageal junction cancer in routine clinical practice: which sample should be used?. Histopathology 2012, 61(1):134-135.
118. Liedtke C., Broglio K., Moulder S., Hsu L., Kau S.W., Symmans W.F., Albarracin C., Meric-Bernstam F., Woodward W., Theriault R.L., Kiesel L., Hortobagyi G.N., Pusztai L., Gonzalez-Angulo A.M. Prognostic impact of discordance between triple-receptor measurements in primary and recurrent breast cancer. Ann. Oncol. 2009, 20(12):1953-1958.
119. Niikura N., Liu J., Hayashi N., Mittendorf E.A., Gong Y., Palla S.L., Tokuda Y., Gonzalez-Angulo A.M., Hortobagyi G.N., Ueno N.T. Loss of human epidermal growth factor receptor 2 (HER2) expression in metastatic sites of HER2-overexpressing primary breast tumors. J. Clin. Oncol. 2012, 30(6):593-599.
120. Bozzetti C., Negri F.V., Lagrasta C.A., Crafa P., Bassano C., Tamagnini I., Gardini G., Nizzoli R., Leonardi F., Gasparro D., Camisa R., Cavalli S., Silini E.M., Ardizzoni A. Comparison of HER2 status in primary and paired metastatic sites of gastric carcinoma. Br. J. Cancer 2011, 104(9):1372-1376.